STOCK TITAN

Xilio Therapeutics to Present at Morgan Stanley 20th Annual Global Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Xilio Therapeutics, a biotechnology company focused on immuno-oncology therapies, will participate in a virtual fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference on September 13, 2022, at 2:55 p.m. ET. The event will be accessible via a live webcast on the company’s website, with a replay available for 30 days post-event. Xilio is advancing its proprietary GPS platform to engineer tumor-selective cytokines and checkpoint inhibitors, including clinical-stage programs XTX101 and XTX202.

Positive
  • None.
Negative
  • None.

WALTHAM, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-selective immuno-oncology therapies for people living with cancer, today announced that the company will participate virtually in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference on Tuesday, September 13, 2022, at 2:55 p.m. ET.

A live webcast of the presentation can be accessed under “Events & Presentations” in the Investors & Media section of the Xilio Therapeutics website at https://ir.xiliotx.com/. A replay of the webcast will be archived on the website for 30 days following the presentation.

About Xilio Therapeutics

Xilio Therapeutics is a clinical-stage biotechnology company focused on harnessing the immune system to achieve deep and durable clinical responses to improve the lives of patients with cancer. The company is using its proprietary geographically precise solutions (GPS) platform to rapidly engineer novel molecules, including cytokines and other biologics, that are designed to optimize their therapeutic index. These molecules are designed to localize activity within the tumor microenvironment without systemic effects, resulting in the potential to achieve enhanced anti-tumor activity. Xilio is building a pipeline of wholly owned, tumor-selective, GPS-enabled cytokine and checkpoint inhibitor product candidates, including its clinical-stage programs, XTX101, a tumor-selective anti-CTLA-4 monoclonal antibody, and XTX202, a tumor-selective IL-2, as well as its earlier pipeline, including XTX301, a tumor-selective IL-12. For more information, please visit https://xiliotx.com and follow us on Twitter (@xiliotx) and LinkedIn (Xilio Therapeutics, Inc.).

This press release contains hyperlinks to information that is not deemed to be incorporated by reference in this press release.

For Investor Inquiries:
Melissa Forst
Argot Partners
Xilio@argotpartners.com

For Media Inquiries: 
Julissa Viana
Vice President, Corporate Communications
media@xiliotx.com   


FAQ

What is Xilio Therapeutics participating in on September 13, 2022?

Xilio Therapeutics will participate in a virtual fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference.

What time is the Xilio Therapeutics presentation at the Morgan Stanley Conference?

The presentation is scheduled for September 13, 2022, at 2:55 p.m. ET.

Where can I watch the Xilio Therapeutics presentation?

A live webcast of the presentation will be available on Xilio Therapeutics' website under the 'Events & Presentations' section.

What are the key programs Xilio Therapeutics is developing?

Xilio is developing tumor-selective therapies, including XTX101, a monoclonal antibody, and XTX202, an IL-2, using its GPS platform.

How long will the webcast of the Xilio Therapeutics presentation be available?

The webcast replay will be archived on the Xilio Therapeutics website for 30 days following the presentation.

Xilio Therapeutics, Inc.

NASDAQ:XLO

XLO Rankings

XLO Latest News

XLO Stock Data

38.78M
25.97M
40.92%
33.5%
0.9%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
WALTHAM